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Purpose:Mortality among ﬁrst-year hemodialysis (HD) patients remains unacceptably high.
To address this problem, we estimate the proportions of early HD deaths that are potentially
preventable by modifying known risk factors.
Methods: We included 15,891 HD patients (within 60 days of starting HD) from 21
countries in the Dialysis Outcomes and Practice Patterns Study (1996–2015), a prospective
cohort study. Using Cox regression adjusted for potential confounders, we estimated the
fraction of ﬁrst-year deaths attributable to one or more of twelve modiﬁable risk factors (the
population attributable fraction, AF) identiﬁed from the published literature by comparing
predicted survival based on risk factors observed vs counterfactually set to reference levels.
Results: The highest AFs were for catheter use (22%), albumin <3.5 g/dL (19%), and
creatinine <6 mg/dL (12%). AFs were 5%-9% for no pre-HD nephrology care, no residual
urine volume, systolic blood pressure <130 or ≥160 mm Hg, phosphorus <3.5 or ≥5.5 mg/dL,
hemoglobin <10 or ≥12 g/dL, and white blood cell count >10,000/μL. AFs for ferritin,
calcium, and PTH were <3%. Overall, 65% (95% CI: 59%-71%) of deaths were attributable
to these 12 risk factors. Additionally, the AF for C-reactive protein >10 mg/L was 21% in
facilities where it was routinely measured.
Conclusion: A substantial proportion of ﬁrst-year HD deaths could be prevented by
successfully modifying a few risk factors. Highest priorities should be decreasing catheter
use and limiting malnutrition/inﬂammation whenever possible.
Keywords: hemodialysis, incidence, mortality, attributable fraction, cohort study
Introduction
Mortality risk during the ﬁrst year of chronic hemodialysis (HD) remains high
worldwide, including 21% in the US, and is especially high in the ﬁrst few months
after initiating HD.1–5 Several ﬁndings support the possibility that improvements in
care may improve outcomes for incident HD patients. Clinical practices that may
positively inﬂuence ﬁrst-year mortality, such as pre-end-stage renal disease (ESRD)
nephrology care and use of arteriovenous ﬁstula (AVF) for dialysis, have been
recognized for some time.3,6–8 However, in many countries, a large proportion of
patients start dialysis only a few months after ﬁrst seeing a nephrologist, too soon to
establish surgical vascular access for use at dialysis initiation.6,9 The mean eGFR at
dialysis start has until recently been rising in the US and elsewhere, despite a lack
of evidence for clinical beneﬁt of earlier dialysis treatment.10−14 Patients often start
dialysis several months before needed, missing the opportunity to be adequately
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prepared to start dialysis. As one mitigating strategy, mul-
tidisciplinary programs to optimize preparation for dialysis
may help limit urgent or unnecessarily early dialysis starts
and, in turn, improve patient outcomes,15–17 but structural
barriers and policy misalignments limit their wider imple-
mentation in many countries.18,19
Prior studies have identiﬁed risk factors for early dia-
lysis mortality, but they have not incorporated prevalence
to quantify the impact of these risk factors at the popula-
tion level, i.e., to estimate the proportions of early HD
deaths that are potentially preventable. The population
attributable fraction (AF) approach is an appealing solu-
tion, but is rarely used in the context of time-to-event
outcomes, presumably due to challenges in estimation.
Given the urgent need to appropriately direct resources
to improve outcomes for patients in the ﬁrst year of dia-
lysis, it is imperative to identify the most important risk
factors for early dialysis mortality at the population level.
To this end, our study aim was to quantify the impact –
considering both prevalence and effects on mortality – of
potentially modiﬁable patient and treatment risk factors on
ﬁrst-year HD mortality using a population AF approach
suitable for a time-to-event outcome.
Methods
Data Source
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) is an ongoing international prospective cohort
study of HD patients designed to identify links between
modiﬁable practices and outcomes in HD patients, with
the goal of extending survival and improving quality of
life; the DOPPS helps researchers and clinicians better
understand differences in practice patterns and factors
associated with patient outcomes. This analysis includes
data from 21 countries across DOPPS phases 1–5 (1996–
2015). Participating countries included France, Germany,
Italy, Japan, Spain, United Kingdom, and United States
(US) in DOPPS phases 1–5; Australia and New Zealand
(ANZ), Belgium, Canada, and Sweden in DOPPS phases
2–5; and the Gulf Cooperation Council (GCC, including
Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab
Emirates), China, Russia, and Turkey in DOPPS Phase 5.
At the beginning of each study phase (~3 years each),
DOPPS participants were randomly selected from national
samples of HD facilities within each country to achieve
representative samples of the age ≥18 in-center HD popu-
lation within each country.20,21 The DOPPS Program is
coordinated by Arbor Research Collaborative for Health.
Study approval was obtained by a central institutional
review board (Ethical & Independent Review Services,
Independence, MO). Additional study approval and patient
consent were obtained as required by national and local
ethics committee regulations. All data are housed at Arbor
Research Collaborative for Health and available internally
for research purposes. Data on demographics, comorbid
conditions, laboratory values, and prescriptions were
abstracted from medical records at DOPPS enrollment
using uniform data collection tools. Mortality events
were collected during study follow-up. The population of
interest for this study was patients who enrolled in DOPPS
within 60 days after initiating maintenance HD therapy.
Participants with unknown vintage (time since dialysis
initiation) at DOPPS enrollment (baseline) were excluded;
no other exclusions were made.
Variables
Twelve known risk factors for dying (Table 2) were chosen
from variables measured at baseline. To estimate associa-
tions with mortality, we categorized risk factors into two
groups (high vs low risk) or three groups (if hypothesized
U-shaped association). Cutpoints were based principally
on previous research demonstrating adjusted associations
with mortality.
Statistical Analysis
We used Cox regression, stratiﬁed by DOPPS phase and
country, and accounted for within-facility clustering, to esti-
mate the association between each risk factor and 1-year
mortality among patients with vintage <60 days at DOPPS
entry. Models included all risk factors plus adjustments for
age, sex, black race, body mass index, and 12 comorbidities
(Table 1). Time at risk extended from study enrollment to
the day of death, 7 days after transition to home dialysis, or
facility departure due to transfer or kidney transplantation,
loss to follow-up, end of the study phase, or 1 year after
enrollment. Because we focus on assessing risk factors with
potential interventions at or near HD initiation, we utilized
exposure variables measured at baseline only.
The proportion of observed ﬁrst-year deaths in the study
population attributable to each risk factor was estimated
using the method of Samuelsen and Eide.22 The population
AF for deaths occurring before time t, labeled “AFB(t),”
depends on both the strength of the association (hazard
ratio; HR) and prevalence of the risk factor. The AF is the
estimated percentage of deaths that would not have occurred
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if every patient’s baseline risk-factor value had been in the
reference category (e.g., if no patients dialyzed with
a catheter; no catheter use); this is the maximum potential
impact of eliminating each risk factor and does not necessa-
rily reﬂect what is achievable in clinical practice.23 From the
ﬁtted Cox model, we calculated predicted 1-year survival
using each patient’s observed value of the risk factor
(PredSurv_Obs) and with that risk factor counterfactually
set to the reference value (PredSurv_CF). We then estimated
AFB (t=1 year), hereafter referred to as AF, by (i) summing
(PredSurv_CF – PredSurv_Obs) across all patients, (ii) sum-
ming (1 – PredSurv_Obs) across all patients, and (iii) divid-
ing the result from (i) by the result from (ii). The AF was
estimated for each risk factor and for all risk factors
Table 1 Patient Characteristics by Time on Dialysis (Vintage)
Dialysis Vintage at Study Entry
Patient Characteristic <60 Days >1 Year
N patients (%) 15,891 (18%) 51,565 (58%)
Characteristics
Age (years) 63.4 ± 15.1 62.2 ± 14.8
Sex (% men) 60% 57%
Race (% black) 16% 18%
Vintage (months) 0.4 (0.0, 1.1) 48 (27, 88)
HD-related characteristics
No reported RUV (%) 26% *
No pre-ESRD nephrology care (%) 24% *
Central venous catheter use (%) 57% 15%
Treatment time (min) 209 ± 38 231 ± 38
Blood ﬂow rate (mL/min) 308 ± 89 343 ± 97
Lab and biometric measurements
Pre-dialysis SBP (mm Hg) 147 ± 23 145 ± 23
Body mass index (kg/m2) 26.4 ± 6.3 25.6 ± 6.4
Serum Creatinine (mg/dL) 6.9 ± 3.0 9.2 ± 3.1
Serum Albumin (g/dL) 3.4 ± 0.6 3.8 ± 0.5
WBC count (103 cells/mm3) 7.8 ± 3.0 6.8 ± 2.3
Serum Calcium (mg/dL) 8.6 ± 0.9 9.1 ± 0.8
Serum Phosphorus (mg/dL) 5.2 ± 1.8 5.4 ± 1.7
PTH (pg/mL) 246 (132, 446) 236 (116, 432)
Serum Potassium (mEq/L) 4.5 ± 0.8 5.0 ± 0.8
Hemoglobin (g/dL) 10.0 ± 1.6 11.0 ± 1.5
Serum Ferritin (ng/mL) 207 (100, 405) 448 (192, 769)
Comorbid conditions (%)
Coronary artery disease 41% 40%
Cancer (non-skin) 13% 10%
Other cardiovascular disease 27% 32%
Cerebrovascular disease 15% 16%
Heart failure 34% 29%
Diabetes 50% 42%
Gastrointestinal bleeding 6% 5%
Lung disease 12% 11%
Neurologic disease 9% 10%
Psychiatric disorder 19% 16%
Peripheral vascular disease 23% 22%
Recurrent cellulitis, gangrene 6% 9%
Notes: Mean ± SD, Median (IQR), or % shown. *Pre-ESRD care data were only available for incident patients and RUV was assumed to be minimal for patients on dialysis >1 year.
Abbreviations: HD, hemodialysis; ESRD, end-stage renal disease; SBP, systolic blood pressure; WBC, white blood cell; PTH, parathyroid hormone; RUV, residual urine volume.
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combined. For 3-level factors, we estimated the HR for low
and high levels (vs the “normal” referent) and summed con-
tributions from both categories. To estimate the combined
AF, we counterfactually set all tested risk factors to the
reference level concurrently. We similarly estimated
a combined AF for each of the three groups of variables
related to malnutrition, inﬂammation, and mineral and bone
disorder (MBD) abnormalities.
Analyses were repeated by DOPPS region and study
phase, and by black race within North America. Analyses
within Japan and countries new to DOPPS in phase 5 were
not feasible due to the very small number of deaths.
C-reactive protein (CRP) was not collected in DOPPS
Phase 1 and was not measured in the majority of facilities –
particularly in North America (1% of facilities). CRP
>10 mg/L was thus investigated as a risk factor in a subset
of facilities that routinely measured CRP (in ≥50% of
patients). To compare HD patients at different stages of
their dialysis treatment, we performed secondary analyses
to estimate AFs for other cohorts of patients with baseline
vintage >1 year, and 60 days to 1 year.
We used multiple imputation to deal with missing
covariate data using the Sequential Regression Multiple
Imputation Method by IVEware.24 The proportion of miss-
ing data was below 20% for all model covariates, with the
exception of PTH (42%), no residual urine volume (RUV;
urine output <200 mL/day, 41%), ferritin (36%), pre-
ESRD nephrology care (30%), and albumin (25%).
Conﬁdence intervals (CIs) for HRs and AFs were esti-
mated using clustered bootstrapped re-sampling. Within
each DOPPS phase-country combination, we resampled
patients 100 times and repeated the AF analyses. This
process was repeated for 10 imputations, resulting in
1000 datasets. We then derived the 95% CI as the 2.5th
and 97.5th percentile of these datasets based on the “MI
boot (pooled sample)” procedure described by Schomaker
Table 2 Attributable Fractions for Mortality Risk-Factors, by Baseline Vintage
Risk Factor Vintage <60 Days (N=15,891) Vintage >1 Year (N=51,565)
% Pts HR (95% CI) AF (95% CI) % Pts HR (95% CI) AF (95% CI)
Catheter use 57% 1.52 (1.37–1.71) 22% (17–27%) 15% 1.22 (1.13–1.31) 4% (2–5%)
Albumin <3.5 g/dL 51% 1.51 (1.35–1.68) 19% (14–24%) 22% 1.80 (1.70–1.90) 15% (14–17%)
Creatinine <6 mg/dL 43% 1.32 (1.18–1.48) 12% (7–16%) 14% 1.30 (1.22–1.43) 5% (4–7%)
Lack of pre-ESRD care 26% 1.38 (1.24–1.56) 9% (6–12%) – – –
No reported RUV 32% 1.32 (1.18–1.50) 9% (5–12%) – – –
SBP >160 mm Hg 27% 0.87 (0.78–0.99)
8% (4–12%)
25% 1.01 (0.93–1.09)
8% (5–10%)
SBP <130 mm Hg 23% 1.51 (1.35–1.70) 25% 1.37 (1.26–1.43)
Phosphorus >5.5 mg/dL 39% 1.20 (1.06–1.36)
7% (2–11%)
41% 1.23 (1.16–1.30)
8% (5–10%)
Phosphorus <3.5 mg/dL 13% 1.12 (0.96–1.31) 11% 1.12 (1.03–1.22)
Hemoglobin >12 g/dL 9% 1.04 (0.87–1.27)
6% (1–11%)
23% 0.91 (0.85–0.98)
3% (1–5%)
Hemoglobin <10 g/dL 50% 1.14 (1.02–1.29) 22% 1.28 (1.18–1.36)
WBC count >10,000/μL 19% 1.30 (1.17–1.46) 5% (3–8%) 9% 1.31 (1.21–1.43) 3% (2–4%)
Ferritin >800 ng/mL 8% 1.35 (1.14–1.63) 2% (1–4%) 22% 1.07 (0.99–1.14) 1% (0–3%)
Calcium >9.5 mg/dL 13% 1.09 (0.92–1.27)
0% (0–4%)
30% 1.14 (1.06–1.21)
5% (3–8%)
Calcium <8.4 mg/dL 38% 0.96 (0.86–1.08) 16% 1.15 (1.06–1.26)
PTH >300 pg/mL 39% 0.88 (0.76–1.01)
0% (0–1%)
38% 1.11 (1.03–1.19)
5% (2–9%)
PTH <150 pg/mL 33% 0.92 (0.77–1.04) 34% 1.07 (0.99–1.14)
Combined AF
Malnutrition* – – 29% (23–35%) – – 20% (18–22%)
Inﬂammation* – – 8% (5–10%) – – 4% (2–6%)
MBD abnormality* – – 0% (0–10%) – – 17% (13–21%)
All risk factors – – 65% (59–71%) – – 46% (41–50%)
Notes: Cox models for 12 risk factors chosen a priori, stratiﬁed by DOPPS phase and country, adjusted for all other variables in table, plus age, sex, black race, BMI, and 12
comorbidities listed in Table 1. *Malnutrition variables include low albumin and low creatinine; inﬂammation variables include high WBC and high ferritin; MBD variables
include high or low calcium, phosphorus and PTH; note pre-ESRD care data were only available for incident patients and RUV was assumed to be minimal for patients on
dialysis >1 year; 95% CI: 2.5th and 97.5th percentiles from 1000 runs: 100 bootstrapped samples combined across 10 imputations; negative values of AF could be obtained
when the observed HR was less than 1, and we report the negative AFs and/or CI bounds as 0% to convey that no excess mortality risk was attributable to the exposure.
Abbreviations: HR, Hazard Ratio of 1 year mortality; AF, Attributable Fraction; ESRD, end-stage renal disease; SBP, systolic blood pressure; WBC, white blood cell; MBD,
mineral and bone disorder; RUV, residual urine volume.
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and Heumann.25 All analyses were conducted using SAS
software, version 9.4 (SAS institute, Cary, NC).
Results
Patient Characteristics
Our primary analyses focused on 15,891 incident patients
with vintage <60 days at DOPPS enrollment. Table 1 com-
pares characteristics of these patients to those on dialysis for
>1 year (average 5.9 years) at enrollment. Incident patients
were more likely to dialyze using a catheter and to have RUV,
shorter treatment time, higher white blood cell (WBC) count,
lower hemoglobin, and lower serum values of albumin, crea-
tinine, calcium, potassium, and ferritin. Over the 1 year
follow-up period, the mortality rate was 0.165/year (1937
deaths) among 15,891 patients with baseline vintage <60
days, and 0.131/year (5759 deaths) among 51,565 patients
with vintage >1 year.
Attributable Fractions for Mortality Risk
Factors
In our primary analysis, the risk factors for 1-year mortality
with the largest AFwere catheter use (22%; 95%CI: 17–27%)
and albumin <3.5 g/dL (19%; 95% CI: 14-24%) (Table 2, left
panel). Other risk factors with AF >5% were serum creatinine
<6 mg/dL (AF=12%), lack of pre-ESRD nephrology care
(AF=9%), lack of RUV (AF=9%), pre-dialysis systolic blood
pressure (SBP) out-of-range 130–160 mm Hg (AF=8%),
serum phosphorus out-of-range 3.5–5.5 mg/dL (AF=7%),
and hemoglobin out-of-range 10–12 g/dL (AF=6%). Serum
calcium and PTH were weakly associated with mortality, and
their estimated AFs were not positive. The combined AF was
higher for malnutrition (low albumin and/or low creatinine;
AF=29%) than for inﬂammation (high ferritin and/or high
WBC; AF=8%) or MBD abnormalities (serum calcium, phos-
phorus, and/or PTH out-of-range; AF=0%). Overall, 65%
(95% CI: 59-71%) of ﬁrst-year HD deaths were attributable
to the risk factors in Table 2.
Compared to this “incident” cohort of vintage <60
days, the proportion of deaths attributed to all combined
risk factors was lower among patients with baseline vin-
tage >1 year (AF=46%; 95% CI: 41-50%; Table 2, right
panel). Low albumin had the largest AF (15%). For cathe-
ter use, both the prevalence (15% vs 57%) and magnitude
of the association (HR = 1.22 vs 1.52) were smaller among
patients with baseline vintage >1 year vs <60 days, result-
ing in a much smaller AF (4% vs 22%). In contrast, the AF
for MBD abnormalities was larger in the cohort with
baseline vintage >1 year vs <60 days (17% vs 0%), driven
by stronger associations of calcium and PTH abnormalities
with mortality. The combined AF (95% CI) was 62%
(56%-67%) among patients with baseline vintage 60 days
to 1 year (Supplementary Table 1).
Among incident HD patients, we found a similar com-
bined AF in North America (AF=66%) and Europe/ANZ
(AF=62%) (Table 3). The AFs for individual risk factors
were most different between regions for no RUV (11% in
North America vs 3% in Europe/ANZ), due to higher pre-
valence of no RUV in North America, and out-of-range
hemoglobin (3% in North America vs 14% in Europe/
ANZ), due to stronger HR for Hgb <10 g/dL in Europe/
ANZ. When further stratifying the North America results by
race, we found that the combined AF was 77% (95% CI:
62%-87%) among black patients and 64% (95% CI: 54%-
72%) among non-black patients; the AF for most individual
risk factors was larger among black patients (Supplementary
Table 3). The combined AF (95%CI) was 65% (57%-72%) in
DOPPS phases 1–2 (1996–2004) and 68% (56%-76%) in
DOPPS phases 3–5 (2005–2015) (Supplementary Table 2).
Notable differences included a greater contribution of catheter
use (AF=29% vs 19%) and high ferritin (AF=6% vs 1%) and
a smaller contribution of phosphorus abnormalities (AF=3%
vs 9%) using more recent data (phases 3–5 vs phase 1–2).
In a subset of facilities where CRP was routinely mea-
sured, 40% of the 3,596 incident HD patients had high CRP
(>10mg/L), and the HR (95%CI) for high (vs low) CRP was
1.64 (1.21–2.22). The AF for high CRP was 21%, and the
inclusion of CRP increased the “Inﬂammation” AF from 7%
to 26% and the overall AF from 59% to 62% in this cohort
(Supplementary Table 4).
Discussion
We estimated attributable fractions to identify the most
important clinical risk factors that may potentially be
modiﬁed to reduce the very high mortality rates in the
months soon after dialysis start. Extending beyond existing
literature reliant on strength of association (e.g., hazard
ratio), the most important risk factors have both relatively
strong associations with mortality and are relatively com-
mon (i.e., high prevalence). As such, estimates of attribu-
table fractions provide information about potential impact
of interventions that are more useful to clinical care and
policy decisions. Among generally modiﬁable risk factors,
the most important were catheter use, nutritional/inﬂam-
matory markers (serum albumin, creatinine, and CRP),
lack of pre-dialysis nephrology care, and lack of RUV.
Dovepress Karaboyas et al
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Other common dialysis measures (SBP, Hgb, and phos-
phorus) contributed to lesser extents.
In prior DOPPSwork,2 we showed thatmortality is highest
in the ﬁrst 4 months of dialysis internationally. The mortality
rate in the US still exceeds 0.25/year during the ﬁrst 4 months
of dialysis despite improvements over the past two decades.1
This study is, to our knowledge, the ﬁrst to quantify the
potential for lowering ﬁrst-year HD mortality by modifying
known risk factors for mortality among HD patients, using
a measure of the AF appropriate for survival data.21 Risk
factors with the largest AFs are both strongly associated with
mortality and highly prevalent in this population.
Among practices evaluated, the largest fraction of early
dialysis mortality was attributed to catheter use (AF=22%).
There is widespread recognition of the dangers of catheter
use,3,26 and substantial reductions in catheter use have been
made and sustained over time in several countries, e.g., through
programs such as the Fistula First Breakthrough Initiative
(FFBI) and the CMS ESRD Quality Incentive Program in the
US.27,28 Among patients with vintage >1 year, the AF for
catheter use was only 4% because of much lower prevalence
and a weaker association with mortality than in the early
dialysis period. Nevertheless, successes targeting chronic HD
patients highlight the need for practice and policy changes to
promote reductions in catheter use among new dialysis starts.
Catheter use in the US is remarkably high, at 80% at dialysis
initiation1 and 67% in the ﬁrst 60 days of HD.29 Catheter use
within 60 days of HD start is also high in the GCC (81%),
Belgium (71%), andCanada (68%), while low catheter use has
been achieved in other countries, including Japan (11%), Italy
(42%), and Germany (42%).29 In this context, our ﬁndings
highlight that, in many countries, initiatives to reduce catheter
use may be the most important means to improve outcomes in
new dialysis patients, and that reduction among incident
patients should be prioritized over much smaller gains that
may be realized in longer-term patients.
Table 3 Attributable Fractions for Mortality Risk-Factors Among Incident (<60 Days Vintage) Patients, by Region
Risk Factor North America (N=8972) Europe/ANZ (N=5278)
% pts HR (95% CI) AF (95% CI) % pts HR (95% CI) AF (95% CI)
Catheter use 71% 1.46 (1.27–1.69) 22% (14–29%) 45% 1.50 (1.22–1.83) 18% (9–26%)
Albumin <3.5 g/dL 54% 1.54 (1.32–1.78) 20% (13–26%) 46% 1.45 (1.16–1.82) 17% (7–26%)
Creatinine <6 mg/dL 49% 1.33 (1.15–1.52) 13% (6–18%) 39% 1.30 (1.05–1.64) 10% (2–19%)
Lack of pre-ESRD care 30% 1.34 (1.18–1.57) 8% (5–13%) 21% 1.39 (1.10–1.74) 8% (2–13%)
No reported RUV 41% 1.37 (1.19–1.59) 11% (6–17%) 18% 1.22 (0.94–1.53) 3% (0–8%)
SBP >160 mm Hg 28% 0.88 (0.76–1.03)
9% (3–14%)
23% 0.84 (0.66–1.09)
6% (0–13%)
SBP <130 mm Hg 24% 1.56 (1.35–1.77) 23% 1.44 (1.16–1.79)
Phosphorus >5.5 mg/dL 37% 1.22 (1.05–1.42)
7% (1–12%)
42% 1.12 (0.90–1.38) 5% (0–14%)
Phosphorus <3.5 mg/dL 14% 1.09 (0.90–1.31) 13% 1.14 (0.84–1.50)
Hemoglobin >12 g/dL 10% 1.05 (0.84–1.28)
3% (0–9%)
11% 1.06 (0.75–1.44)
14% (5–23%)
Hemoglobin <10 g/dL 48% 1.07 (0.93–1.23) 46% 1.39 (1.15–1.73)
WBC count >10,000/μL 22% 1.23 (1.07–1.40) 4% (1–7%) 17% 1.42 (1.12–1.78) 6% (2–10%)
Ferritin >800 ng/mL 9% 1.27 (1.02–1.58) 2% (0–4%) 7% 1.50 (1.09–2.03) 3% (1–6%)
Calcium >9.5 mg/dL 10% 1.12 (0.89–1.37)
0% (0–5%)
20% 1.04 (0.78–1.37)
0% (0–9%)
Calcium <8.4 mg/dL 38% 0.97 (0.84–1.11) 31% 0.98 (0.78–1.25)
PTH >300 pg/mL 43% 0.87 (0.74–1.03)
0% (0–3%)
35% 0.88 (0.69–1.14)
0% (0–5%)
PTH <150 pg/mL 30% 0.92 (0.77–1.10) 35% 0.90 (0.71–1.16)
Combined AF
Malnutrition* – – 31% (23–38%) – – 26% (15–35%)
Inﬂammation* – – 6% (3–10%) – – 9% (4–14%)
MBD abnormality* – – 0% (0–11%) – – 0% (0–16%)
All risk factors – – 66% (58–73%) – – 62% (49–72%)
Notes: Cox models stratiﬁed by DOPPS phase and country, adjusted for all other variables in table, plus age, sex, black race, BMI, and 12 comorbidities listed in Table 1;
analyses within Japan and countries new to DOPPS in Phase 5 were not reported due to the very small number of deaths; *Malnutrition variables include low albumin and
low creatinine; inﬂammation variables include high WBC and high ferritin; MBD variables include high or low calcium, phosphorus and PTH; 95% CI: 2.5th and 97.5th
percentiles from 1000 runs: 100 bootstrapped samples combined across 10 imputations; negative values of AF could be obtained when the observed HR was less than 1, and
we report the negative AFs and/or CI bounds as 0% to convey that no excess mortality risk was attributable to the exposure.
Abbreviations: HR, Hazard Ratio of 1 year mortality; AF, Attributable Fraction; ESRD, end-stage renal disease; SBP, systolic blood pressure; WBC, white blood cell; MBD,
mineral and bone disorder; RUV, residual urine volume.
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Lack of pre-ESRD nephrology care had an AF of 9%,
highlighting the need to improve access to care for patients
at high risk for ESRD. Both longer pre-ESRD nephrology
care and greater frequency of patient-nephrologist contact
prior to ESRD have been linked to lower ﬁrst-year
mortality.6,30 The proportion of patients starting dialysis
with little or no pre-ESRD nephrology care remains high
in the US, at 26% in 2015, though improved from 32% in
2011.5,31 The true AF for absent pre-ESRD nephrology
care is likely higher than our estimate of 9%, because the
statistical model included potential mediators on the causal
pathway between pre-ESRD nephrology care and clinical
outcomes, such as AV access use and nutritional markers.
AFs for low serum albumin and creatinine levels were
19% and 12%, respectively, highlighting the need to opti-
mize nutrition and physical condition for patients
approaching kidney failure and after starting dialysis.32
The prevalence, and consequently the AF, of these risk
factors was lower among patients on dialysis >1 year,
likely due to early death of older and frail patients.
We found an AF of 21% for CRP >10 mg/L, higher than
for other inﬂammatory indicators (5% for WBC >10,000/μL,
2% for ferritin >800 ng/mL). These results highlight the
importance of inﬂammation, and suggest the value of mea-
suring CRP in the clinic. In contrast to North America, many
nephrologists in Europe and Japan appear to have incorpo-
rated CRP years ago into the panel of data that routinely
inform decision-making in clinical dialysis practice.
Non-monotonic associations of several laboratory and
biometric measures with mortality have been reported
previously and merit mention in the context of this
study. Both low and high pre-dialysis SBP are common
(>20%), but the association with elevated mortality is
much clearer for low than high SBP.2,33 Though confound-
ing due to poor health status partly explains the associa-
tion at lower SBP levels, greater emphasis on limiting
treatment-related hypotension appears warranted; doing
so soon after HD initiation can have additional value by
preserving RUV. Other potential interventions to preserve
RUV include starting patients on incremental dialysis and
avoiding hemodynamic instability by managing the ultra-
ﬁltration volume on HD. While it is not realistic to restore
RUV to prevalent HD patients, these potential steps can be
taken at or around the time of dialysis initiation.
While both low and high phosphorus are associated with
elevated mortality, high phosphorus (>5.5 mg/dL) is excep-
tionally common at ~40% across dialysis vintages, so therapy
directly targeting hyperphosphatemia should be a priority
before and after initiating HD.34 Management of low phos-
phorus (<3.5 mg/dL, prevalence ~10%) is part of broader
nutritional interventions targeting low serum albumin, low
serum creatinine, and other measures. The AF for other
MBD markers – PTH and serum calcium – was larger in the
vintage >1 year cohort than during the ﬁrst year of dialysis,
potentially explained in part by the accumulation of calcium
leading to vascular calciﬁcation. Consensus regarding hemo-
globin targets has settled generally in the 10–12 g/dL
range.35,36 In our analysis, the AF for hemoglobin is highest
in the ﬁrst year of HD (6%), driven by an excess of patients
(50%) with hemoglobin <10 g/dL at or near HD initiation.
Anemia of kidney disease tends to be undertreated in the non-
dialysis setting, with “catch up” treatment after dialysis start.1
The current analysis supports the potential value of treating
patients earlier in the transition to kidney failure.
Consideration of our ﬁndings is warranted in the context of
real-world efforts to improve outcomes.Over a decade ago, the
RightStart program was a US-based systematic case manage-
ment approach during the ﬁrst three months of dialysis that
achieved reductions in ﬁrst-year mortality, though it was
unclear which of the program’s interventions were most
effective.15,16 Focus in the US in recent years has been on
ESRD Seamless Care Organizations (ESCO), which carry
accountability for clinical and ﬁnancial outcomes for
Medicare dialysis beneﬁciaries as part of Medicare’s accoun-
table care organization demonstration projects.37 To increase
their impact, some ESCOs have been moving “upstream” to
provide education and other services for CKD patients not yet
on dialysis,18,19 reﬂecting the recognition that improving out-
comes on dialysis necessitates adequate preparation prior to
dialysis. However, policy changes may be warranted to
directly promote accountability for adequate preparation for
dialysis.
Strengths of this study include uniform data collection in
21 countries. We also used state-of-the-art statistical methods
for estimating AFs in a survival context and calculating con-
ﬁdence intervals using bootstrapped imputations. This study
has some limitations. While qualitative interpretation by rank-
ing AFs may identify highest priority targets to improve
survival, the AFs should be interpreted cautiously as the max-
imum potential impact of eliminating each risk factor; the
expected impact of doing so in practice is uncertain and is
likely less than the estimated AFs.23 For example, if catheter
use cannot realistically be reduced to zero because some
catheter patients may not be candidates for AV access, then
the expected impact of practice changes will be less than the
estimated AF of 22%. Further, our AF estimates for individual
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risk factors may be biased due to lack of control for unmea-
sured risk factors, measurement error, or over-adjustment for
mediators. In addition, AF estimates for continuous risk fac-
tors depend on how cutpoints are deﬁned. We relied on pre-
vious ﬁndings and guidelines for target values to categorize
these risk factors.
The goal of this study was not to identify interventions
that most effectively reduce or eliminate key risk factors;
these are important next steps. In some cases, directed treat-
ments merit study, such as preserving RUV by minimizing
exposure to intradialytic hypotension and nephrotoxic
agents. To reduce catheter use, multilevel interventions may
be required, including optimizing technical approaches,
facility practices and services, patient and family education,
and promoting a “culture” of ﬁstula use.17,29,38,39 Risk factors
such as low serum albumin and creatinine levels, reﬂecting
poor nutrition and frailty, can have socioeconomic as well as
medical determinants, and reducing disparities related to
social support, access to care, and health care coverage (in
the US and certain other countries) merits attention.18,19
The key innovation of this study was to identify the most
important clinical risk factors for ﬁrst-year dialysis mortality
from a population health perspective, doing so using attribu-
table fractions that incorporate risk-factor prevalence rather
than strength of association alone. Our ﬁndings indicate that
a substantial proportion of the ﬁrst-year deaths among HD
patients could be potentially prevented by favorably altering
the distribution of several modiﬁable risk factors, prioritizing
attention to risk factors that have the greatest impact. These
include reducing catheter use, raising pre-ESRD nephrology
care, avoiding or treating malnutrition/inﬂammation, and
preserving RUV. Focus on interventions that most effectively
reduce these key risk factors may impact mortality in the
ﬁrst year of hemodialysis and beyond.
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